AVXL vs CRNX
AVXL: A clinical-stage biopharma company developing precision medicine treatments for Alzheimer's, Parkinson's, and rare CNS diseases by targeting the sigma-1 receptor. CRNX: Crinetics Pharmaceuticals is a clinical-stage biotechnology company developing small molecule precision medicines for rare endocrine diseases and related tumors.
Side-by-side fundamentals
| Metric | AVXL | CRNX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $2.50 | $83.86 | |
| Market cap as of 2026-08-05 | $232M | $8.8B | |
| PEG as of 2026-08-05 | n/a | -0.73 | |
| Net margin as of 2026-08-05 | n/a | -2747.2% | |
| Gross margin as of 2026-08-05 | n/a | +86.0% | |
| Operating margin as of 2026-08-05 | n/a | -3020.3% | |
| ROE as of 2026-08-05 | -38.8% | -44.0% | AVXL higher |
| ROA as of 2026-08-05 | -35.0% | -39.6% | AVXL higher |
| Debt / equity as of 2026-08-05 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-05 | n/a | +2277.5% | |
| Beta as of 2026-08-05 | 1.15 | 0.02 | |
| 1-year return as of 2026-07-27 close | -79.4% | +197.2% | CRNX higher |
Fundamentals: market data, as of 2026-08-05. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.